What do systematic reviews say?

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate probably leads to higher clinical improvement American College of Rheumatology 50%… compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 3.3 [2.3, 4.6]
  4 studies · 1165 participants
  Moderate

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in clinical remission (Disease Activity Score‐28 joint count < 2.6)… compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 9.1 [0.76, 108.2]
  2 studies · 834 participants
  Moderate

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate leads to higher physical function (HAQ‐DI MCID = ‐0.22) Analysis 1.10 compared with methotrexate monotherapy (high certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 1.6 [1.2, 2.1]
  4 studies · 1161 participants
  High

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in no radiographic progression in total Genant‐modified Sharp score… compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 1.2 [1, 1.4]
  1 study · 476 participants
  Moderate

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 2 [1.1, 3.4]
  4 studies · 1526 participants
  High

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 2.1 [0.88, 4.9]
  5 studies · 1385 participants
  Moderate

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 1 [0.69, 1.5]
  4 studies · 1280 participants
  Moderate

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 100 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

It is very uncertain whether summary of findings table ‐ Exercise plus usual pharmacological care changes withdrawals due to any reason compared with usual pharmacological care alone (very low certainty).

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  RR 0.92 [0.53, 1.6]
  6 studies · 235 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 119 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 182 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 184 participants
  Moderate

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 121 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

It is very uncertain whether summary of findings table ‐ Exercise plus usual pharmacological care changes withdrawals due to any reason compared with another intervention (education, joint aids, or relaxation) plus… (very low certainty).

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  RR 0.89 [0.13, 5.94]
  7 studies · 317 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found